Scientists publish seminal paper and announce project to develop biomarkers of aging

November 21, 2016, Biogerontology Research Foundation

Today the Biogerontology Research Foundation announced the international collaboration on signaling pathway perturbation-based transcriptomic biomarkers of aging. On November 16th scientists at the Biogerontology Research Foundation alongside collaborators from Insilico Medicine, Inc, the Johns Hopkins University, Albert Einstein College of Medicine, Boston University, Novartis, Nestle and BioTime Inc. announced the publication of their proof of concept experiment demonstrating the utility of a novel approach for analyzing transcriptomic, metabolomic and signalomic data sets, titled iPANDA, in Nature Communications.

"Given the high volume of data being generated in the life sciences, there is a huge need for tools that make sense of that data. As such, this new method will have widespread applications in unraveling the molecular basis of age-related diseases and in revealing biomarkers that can be used in research and in clinical settings. In addition, tools that help reduce the complexity of biology and identify important players in disease processes are vital not only to better understand the underlying mechanisms of age-related disease but also to facilitate a personalized medicine approach. The future of medicine is in targeting diseases in a more specific and personalized fashion to improve clinical outcomes, and tools like iPANDA are essential for this emerging paradigm," said Joao Pedro de Megalhaes, PhD, a trustee of the Biogerontology Research Foundation.

The algorithm, iPANDA, applies to complex gene expression data sets and signal pathway activation data for the purposes of analysis and integration, and their proof of concept article demonstrates that the system is capable of significantly reducing noise and dimensionality of transcriptomic data sets and of identifying patient-specific pathway signatures associated with that characterize their response to Toxicol-based neoadjuvant therapy.

The system represents a substantially new approach to the analysis of microarray data sets, especially as it pertains to data obtained from multiple sources, and appears to be more scalable and robust than other current approaches to the analysis of transcriptomic, metabolomic and signalomic data obtained from different sources. The system also has applications in rapid biomarker development and , discrimination between distinct biological and clinical conditions, and the identification of functional pathways relevant to disease diagnosis and treatment, and ultimately in the development of personalized treatments for .

"iPANDA represents a significant contribution to the emerging application of algorithms to transcriptomic and signalomic data analysis, and is a substantial extension of the approach the team put forward previously through their OncoFinder algorithm. The capacity of iPANDA to reduce the dimensionality of transcriptomic and signalomic makes it a very useful tool in rapid biomarker development and accelerated drug discovery, in formulating personalized treatments to promote improved clinical outcomes, in bringing the results of in silico analyses closer to their experimental counterparts, and in the analysis of transcriptomic and signalomic data originating from multiple sources. While the team predicted and compared the response of breast cancer patients to Taxol-based neoadjuvant therapy as their proof of concept, the application of this approach to patient-specific responses to biomedical gerontological interventions (e.g. to geroprotectors, which is a clear focus of the team's past efforts), to the development of both generalized and personalized biomarkers of ageging, and to the characterization and analysis of minute differences in ageging over time, between individuals, and between different organisms would represent a promising and exciting future application" said Franco Cortese, Deputy Director of the Biogerontology Research Foundation.

"This latest achievement on the part of Alex Zhavoronkov and his team is yet another step toward greater heights and bolder frontiers in the application of deep learning to personalized medicine, biomarker characterization and accelerated drug discovery. The publication of this proof-of-concept experiment in Nature Communications is a testament to the importance of their latest accomplishment, to the substantial progress that the team has made over the past 2 years, and to the great heights and ground-breaking achievements that they are sure to reach in the years to come. It represents yet another successful validation of the usefulness of their entire approach - namely, the application of deep learning to biomedicine, geroscience and P3 (personalized, precision and preventative) medicine." said Dmitry Kaminskiy, Managing Trustee of the Biogerontology Research Foundation.

Explore further: Personalized medicine leads to better outcomes for patients with cancer

More information: Ivan V. Ozerov et al, In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development, Nature Communications (2016). DOI: 10.1038/NCOMMS13427

Related Stories

Personalized medicine leads to better outcomes for patients with cancer

June 6, 2016
In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes ...

BGRF announces OncoFinder algorithm for reducing errors in transcriptome analysis

August 18, 2014
Scientists from the Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, propose a new concept for signalome-wide analysis ...

A vision for medicine precision with new disease data link-up

March 23, 2016
Vast amounts of data generated by screening patients for diseases like cancer and arthritis at The University of Manchester will now be used to improve treatment and drug safety in partnership with the University of Dundee.

Precision medicine can widen cancer care options: studies (Update)

June 4, 2016
Using a patient's individual tumor biomarkers to determine the best treatment can improve success rates, studies showed Saturday.

Researchers report clinical utility of personalized medicine program for cancer patients

June 1, 2016
Scientists from the Icahn School of Medicine at Mount Sinai developed and tested a personalized cancer therapy program using an integrated genomic approach that led to therapeutic recommendations for 91 percent of patients. ...

Recommended for you

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

AI matched, outperformed radiologists in screening X-rays for certain diseases

November 21, 2018
In a matter of seconds, a new algorithm read chest X-rays for 14 pathologies, performing as well as radiologists in most cases, a Stanford-led study says.

Machine learning can be used to predict which patients require emergency admission

November 20, 2018
Machine learning—a field of artificial intelligence that uses statistical techniques to enable computer systems to 'learn' from data—can be used to analyse electronic health records and predict the risk of emergency hospital ...

Researchers stop 'sneaky' cancer cells in their tracks

November 20, 2018
A new study by University of Minnesota biomedical engineers shows how they stopped cancer cells from moving and spreading, even when the cells changed their movements. The discovery could have a major impact on millions of ...

A Trojan horse delivery method for miRNA-enriched extracellular vesicles

November 20, 2018
A method for large-scale production of extracellular vesicles enriched with specific microRNAs (miRNAs) has been developed in the Wake Forest Institute for Regenerative Medicine (WFIRM) labs, offering a manufacturing standardization ...

Researchers hope to be able to replace dysfunctional brain cells

November 20, 2018
A new study by researchers at Karolinska Institutet supports the theory that replacement of dysfunctional immune cells in the brain has therapeutic potential for neurodegenerative diseases like ALS and Alzheimer's disease. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.